

Raffaele De Caterina

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7964955/publications.pdf>

Version: 2024-02-01

320
papers

43,204
citations

12330

69
h-index

2178

202
g-index

335
all docs

335
docs citations

335
times ranked

37677
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: A randomized clinical trial. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2023, 165, 58-67.e4.	0.8	38
2	Factors for heterogeneous outcomes of angina and myocardial ischemia without obstructive coronary atherosclerosis. <i>Journal of Internal Medicine</i> , 2022, 291, 197-206.	6.0	3
3	Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 227-235.	3.0	6
4	Sodium-glucose cotransporter type 2 inhibitors prevent ponatinib-induced endothelial senescence and dysfunction: A potential rescue strategy. <i>Vascular Pharmacology</i> , 2022, 142, 106949.	2.1	13
5	Perceived vs. objective frailty in patients with atrial fibrillation and impact on anticoagulant dosing: an ETNA-AF-Europe sub-analysis. <i>Europace</i> , 2022, 24, 1404-1411.	1.7	16
6	Response to "Current evidence and future perspective for the management of left sided prosthetic valve thrombosis". <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, , .	3.0	0
7	Sex-related differential susceptibility to ponatinib cardiotoxicity and differential modulation of the Notch1 signalling pathway in a murine model. <i>Journal of Cellular and Molecular Medicine</i> , 2022, , .	3.6	6
8	Bleeding risk score: limits and practicability. <i>Heart</i> , 2022, 108, 246-248.	2.9	1
9	OUP accepted manuscript. <i>European Heart Journal</i> , 2022, , .	2.2	3
10	Endothelial Progenitor Cells in Coronary Atherosclerosis and Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. <i>Cardiovascular Revascularization Medicine</i> , 2022, 42, 94-99.	0.8	5
11	Rivaroxaban in mitral stenosis (RISE MS): A pilot randomized clinical trial. <i>International Journal of Cardiology</i> , 2022, 356, 83-86.	1.7	6
12	A Prospective Study to Evaluate the Effectiveness of Edoxaban for the Resolution of Left Atrial Thrombosis in Patients with Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2022, 11, 1945.	2.4	0
13	Endothelial Progenitor Cells in Coronary Artery Disease: From Bench to Bedside. <i>Stem Cells Translational Medicine</i> , 2022, 11, 451-460.	3.3	9
14	A Therapeutic Pathway in Patients with Chronic Coronary Syndromes: Proposal for Optimization. <i>Journal of Clinical Medicine</i> , 2022, 11, 2091.	2.4	0
15	Fast vs. ultraslow thrombolytic infusion regimens in patients with obstructive mechanical prosthetic valve thrombosis: a pilot randomized clinical trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 668-676.	3.0	2
16	The non-vitamin K antagonist oral anticoagulants and heparin-induced prolongation of the activated coagulation time. <i>Vascular Pharmacology</i> , 2022, 144, 106994.	2.1	0
17	Response to "Non-vitamin K antagonist oral anticoagulants (NOACs) in preventing thromboembolism in atrial fibrillation patients with moderate to severe mitral stenosis: Results from a pilot trial". <i>International Journal of Cardiology</i> , 2022, , .	1.7	0
18	Exercise-Induced Pulmonary Hypertension Is Associated with High Cardiovascular Risk in Patients with HIV. <i>Journal of Clinical Medicine</i> , 2022, 11, 2447.	2.4	1

#	ARTICLE	IF	CITATIONS
19	Left Atrial Remodeling and Stroke in Patients With Sinus Rhythm and Normal Ejection Fraction: ARICâ€NCS. <i>Journal of the American Heart Association</i> , 2022, 11, e024292.	3.7	4
20	Detecting the vulnerable carotid plaque: the Carotid Artery Multimodality imaging Prognostic study design. <i>Journal of Cardiovascular Medicine</i> , 2022, 23, 466-473.	1.5	3
21	Clinical Performance of Oral Anticoagulants in Elderly with Atrial Fibrillation and Low Body Weight: Insight into Italian Cohort of PREFER-AF and PREFER-AF Prolongation Registries. <i>Journal of Clinical Medicine</i> , 2022, 11, 3751.	2.4	5
22	Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f30-f39.	3.0	33
23	Insulin-treated versus noninsulin-treated diabetes and risk of ischemic stroke in patients with atrial fibrillation. <i>Vascular Pharmacology</i> , 2021, 136, 106809.	2.1	5
24	PCSK9 and atherosclerosis: Looking beyond LDL regulation. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13459.	3.4	45
25	Antithrombotic management and outcomes of patients with atrial fibrillation treated with NOACs early at the time of market introduction: Main results from the PREFER in AF Prolongation Registry. <i>Internal and Emergency Medicine</i> , 2021, 16, 591-599.	2.0	4
26	Preâ€treatment highâ€sensitivity troponin T for the shortâ€term prediction of cardiac outcomes in patients on immune checkpoint inhibitors. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13400.	3.4	17
27	Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and The Netherlands: insights from the ETNA-AF-Europe study. <i>Acta Cardiologica</i> , 2021, 76, 431-439.	0.9	2
28	Is coronary flow velocity reserve just a marker of a higher atherosclerotic burden?. <i>European Heart Journal</i> , 2021, 42, 1444-1445.	2.2	1
29	Lipid-Lowering Therapy in Patients with Coronary Heart Disease and Prior Stroke: Mission Impossible?. <i>Journal of Clinical Medicine</i> , 2021, 10, 886.	2.4	5
30	Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program. <i>Journal of Clinical Medicine</i> , 2021, 10, 573.	2.4	14
31	Antiplatelet therapy in patients with acute coronary syndromes and thrombocytopenia: awaiting for evidence. <i>European Heart Journal - Case Reports</i> , 2021, 5, yta577.	0.6	0
32	Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas. <i>Open Heart</i> , 2021, 8, e001471.	2.3	7
33	Factors associated with the dosing of edoxaban for stroke prevention in patients with atrial fibrillation from South Korea and Taiwan: 1-year data from the Global ETNA-AF Program. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 485-490.	1.4	6
34	Extent and progression of atherosclerosis in carotid and subclavian arteries: the Carotid Artery Subclavian Artery study. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 652-656.	1.5	1
35	Patient Preferences of Low-Dose Aspirin for Cardiovascular Disease and Colorectal Cancer Prevention in Italy: A Latent Class Analysis. <i>Patient</i> , 2021, 14, 661-672.	2.7	2
36	Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>European Heart Journal</i> , 2021, 42, 2630-2642.	2.2	69

#	ARTICLE	IF	CITATIONS
37	Clustering of blood cell count abnormalities and future risk of death. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13562.	3.4	3
38	Excessive Orthostatic Changes in Blood Pressure Are Associated With Incident Heart Failure in Older Men. <i>Hypertension</i> , 2021, 77, 1481-1489.	2.7	2
39	Connexin 43 and Connexin 26 Involvement in the Ponatinib-Induced Cardiomyopathy: Sex-Related Differences in a Murine Model. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5815.	4.1	12
40	COVID-19 cardiological research in France: A nationwide perspective. <i>Archives of Cardiovascular Diseases</i> , 2021, 114, 337-339.	1.6	0
41	Telomerase/myocardin expressing mesenchymal cells induce survival and cardiovascular markers in cardiac stromal cells undergoing ischaemia/reperfusion. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 5381-5390.	3.6	9
42	COVID-19-related cardiac complications from clinical evidences to basic mechanisms: opinion paper of the ESC Working Group on Cellular Biology of the Heart. <i>Cardiovascular Research</i> , 2021, 117, 2148-2160.	3.8	26
43	Many Good Reasons to Switch from Vitamin K Antagonists to Non-Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2021, 10, 2866.	2.4	5
44	Impact of Weight on Clinical Outcomes of Edoxaban Therapy in Atrial Fibrillation Patients Included in the ETNA-AF-Europe Registry. <i>Journal of Clinical Medicine</i> , 2021, 10, 2879.	2.4	7
45	Reclassification, Thromboembolic, and Major Bleeding Outcomes Using Different Estimates of Renal Function in Anticoagulated Patients With Atrial Fibrillation: Insights From the PREFER-in-AF and PREFER-in-AF Prolongation Registries. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e006852.	2.2	11
46	A highly-detailed anatomical study of normal pericardial structures as revealed by in-vivo computed tomography and magnetic resonance images and ex-vivo novel 3D reconstructions from Visible Human Server. <i>Imaging</i> , 2021, 13, 1-12.	0.3	1
47	The JAK-STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms. <i>European Heart Journal</i> , 2021, 42, 4389-4400.	2.2	61
48	Interpreting myocardial infarction analyses in ISCHEMIA: separating facts from fallacy. <i>European Heart Journal</i> , 2021, 42, 2986-2989.	2.2	2
49	Is there equivalence between PCI and CABG surgery in long-term survival of patients with diabetes? Importance of interpretation biases and biological plausibility. <i>European Heart Journal</i> , 2021, 43, 68-70.	2.2	4
50	Exercise-induced pulmonary hypertension in HIV patients: Association with poor clinical and immunological status. <i>Vascular Pharmacology</i> , 2021, 139, 106888.	2.1	4
51	Coronary Artery Anomalies. <i>Circulation</i> , 2021, 144, 983-996.	1.6	77
52	Eighty years of oral anticoagulation: Learning from history. <i>Vascular Pharmacology</i> , 2021, 141, 106918.	2.1	2
53	OUP accepted manuscript. <i>European Heart Journal</i> , 2021, , .	2.2	9
54	A case report of multisite arterial thrombosis in a patient with coronavirus disease 2019 (COVID-19). <i>European Heart Journal - Case Reports</i> , 2021, 5, ytaa339.	0.6	8

#	ARTICLE	IF	CITATIONS
55	ST-segment/heart rate hysteresis improves the exercise testing accuracy for coronary artery detection in asymptomatic patients with severe aortic stenosis. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 323-325.	1.5	2
56	Coffee Bioactive N-Methylpyridinium Attenuates Tumor Necrosis Factor (TNF)- α -Mediated Insulin Resistance and Inflammation in Human Adipocytes. <i>Biomolecules</i> , 2021, 11, 1545.	4.0	4
57	Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease. <i>Circulation</i> , 2021, 144, 1323-1343.	1.6	35
58	The Vessels-Bone Axis: Iliac Artery Calcifications, Vertebral Fractures and Vitamin K from VIKI Study. <i>Nutrients</i> , 2021, 13, 3567.	4.1	6
59	Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice. <i>Journal of Clinical Medicine</i> , 2021, 10, 5337.	2.4	2
60	Nutrigenomic Effect of Hydroxytyrosol in Vascular Endothelial Cells: A Transcriptomic Profile Analysis. <i>Nutrients</i> , 2021, 13, 3990.	4.1	8
61	531 Neuroimaging assessment of unilateral asymptomatic carotid artery stenosis: preliminary results of the carotid artery multi-modality imaging prognostic (camp) study. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.1	0
62	651â€œPrevention of contrast induced nephropathy with urine alkalinization: the final results of the TEATE study. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.1	0
63	Association of Circulating Heme Oxygenase-1, Lipid Profile and Coronary Disease Phenotype in Patients with Chronic Coronary Syndrome. <i>Antioxidants</i> , 2021, 10, 2002.	5.1	2
64	The Nutrigenetics of Cardiovascular Disease. , 2020, , 355-360.		1
65	Cholesterol Lowering and Stroke: No Longer Room for Pleiotropic Effects of Statins â€œ Confirmation from PCSK9 Inhibitor Studies. <i>American Journal of Medicine</i> , 2020, 133, 95-99.e6.	1.5	14
66	Why include the humanities in medical studies?. <i>Internal and Emergency Medicine</i> , 2020, 15, 523-524.	2.0	0
67	Association of the European Society of Cardiology echocardiographic probability grading for pulmonary hypertension with short and mid-term clinical outcomes after heart valve surgery. <i>Vascular Pharmacology</i> , 2020, 125-126, 106648.	2.1	7
68	Aspirin Therapy for Primary Prevention: The Case for Continuing Prescribing to Patients at High Cardiovascular Riskâ€œA Review. <i>Thrombosis and Haemostasis</i> , 2020, 120, 199-206.	3.4	5
69	Left Ventricular Size Predicts Clinical Benefit After Percutaneous Mitral Valve Repair for Secondary Mitral Regurgitation: A Systematic Review and Meta-Regression Analysis. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 857-864.	0.8	5
70	Endothelial Dysfunction, Fibrinolytic Activity, and Coagulation Activity in Patients With Atrial Fibrillation According to Type II Diabetes Mellitus Status. <i>American Journal of Cardiology</i> , 2020, 125, 751-758.	1.6	8
71	Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial. <i>Circulation</i> , 2020, 141, 10-20.	1.6	24
72	Challenges in ischaemic heart disease: not sleeping enough, not brushing your teeth, and skipping breakfastâ€œthree ways of increasing your risk of Amyocardial infarction?. <i>European Heart Journal Supplements</i> , 2020, 22, L57-L60.	0.1	3

#	ARTICLE	IF	CITATIONS
73	Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 642-651.	1.6	9
74	The <i>European Heart Journal</i> : leading the fight to reduce the global burden of cardiovascular disease. <i>European Heart Journal</i> , 2020, 41, 3113-3116.	2.2	6
75	Growth Differentiation Factor 15 in Severe Aortic Valve Stenosis: Relationship with Left Ventricular Remodeling and Frailty. <i>Journal of Clinical Medicine</i> , 2020, 9, 2998.	2.4	8
76	Optimal Antithrombotic Treatment of Patients with Atrial Fibrillation Early after an Acute Coronary Syndrome—Triple Therapy, Dual Antithrombotic Therapy with an Anticoagulant—Or, Rather, Temporary Dual Antiplatelet Therapy?. <i>Journal of Clinical Medicine</i> , 2020, 9, 2673.	2.4	5
77	Evaluation of the Age, Biomarkers, and Clinical History—Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials. <i>JAMA Network Open</i> , 2020, 3, e2015943.	5.9	5
78	Empagliflozin reduces the senescence of cardiac stromal cells and improves cardiac function in a murine model of diabetes. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 12331-12340.	3.6	24
79	Mortality Prediction of the CHA2DS2-VASc Score, the HAS-BLED Score, and Their Combination in Anticoagulated Patients with Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2020, 9, 3987.	2.4	15
80	Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. <i>Lancet</i> , The, 2020, 396, 1745-1757.	13.7	192
81	Transplantation of telomerase/myocardin-co-expressing mesenchymal cells in the mouse promotes myocardial revascularization and tissue repair. <i>Vascular Pharmacology</i> , 2020, 135, 106807.	2.1	13
82	Imaging of the vulnerable carotid plaque. <i>Neurology</i> , 2020, 94, 922-932.	1.1	30
83	Controversial Relationship Between Renin-Angiotensin System Inhibitors and Severity of COVID-19. <i>Hypertension</i> , 2020, 76, 312-313.	2.7	9
84	Commentary: Temporarily omitting oral anticoagulants early after stenting for acute coronary syndromes patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2020, 318, 82-85.	1.7	6
85	Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI. <i>American Journal of Medicine</i> , 2020, 133, 1302-1312.	1.5	1
86	Where are clots in atrial fibrillation? Did we have the wrong assumptions over the last decades?. <i>Europace</i> , 2020, 22, 845-846.	1.7	4
87	Effects of Olive Oil on Blood Pressure: Epidemiological, Clinical, and Mechanistic Evidence. <i>Nutrients</i> , 2020, 12, 1548.	4.1	34
88	Thromboembolic and bleeding risk in obese patients with atrial fibrillation according to different anticoagulation strategies. <i>International Journal of Cardiology</i> , 2020, 318, 67-73.	1.7	11
89	Antithrombotic treatment strategies after PCI. <i>Lancet</i> , The, 2020, 395, 865.	13.7	2
90	Comparing TEE- vs Non-TEE-guided cardioversion of atrial fibrillation: The ENSURE-CAF trial. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13221.	3.4	2

#	ARTICLE	IF	CITATIONS
91	Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial. Journal of the American College of Cardiology, 2020, 75, 1145-1155.	2.8	28
92	Ponatinib Induces Vascular Toxicity through the Notch-1 Signaling Pathway. Journal of Clinical Medicine, 2020, 9, 820.	2.4	16
93	Effect of concomitant antiplatelet agents on clinical outcomes in the edoxaban vs warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomized trial. Clinical Research in Cardiology, 2020, 109, 1374-1380.	3.3	4
94	From short-term blood pressure variability to atherosclerosis: Relative roles of vascular stiffness and endothelial dysfunction. Journal of Clinical Hypertension, 2020, 22, 1218-1227.	2.0	17
95	Isolated Exercise-Induced Pulmonary Hypertension Associates with Higher Cardiovascular Risk in Scleroderma Patients. Journal of Clinical Medicine, 2020, 9, 1910.	2.4	8
96	Should We Continue Assessing Glomerular Filtration Rate with the Cockcroft-Gault Formula in NOAC-Treated Patients? The Magnitude of the Problem. Journal of Clinical Medicine, 2020, 9, 1893.	2.4	8
97	Benefit of dual antithrombotic therapy with direct oral anticoagulants in patients with atrial fibrillation undergoing percutaneous coronary intervention: a systematic review and metaanalysis of randomized clinical trials. Internal and Emergency Medicine, 2020, 15, 1093-1104.	2.0	5
98	Prevention of contrast-induced nephropathy with urine alkalinization: the TEATE study design. Journal of Cardiovascular Medicine, 2020, 21, 65-72.	1.5	2
99	Vitamin K antagonists and osteoporotic fractures: insights from comparisons with the NOACs. European Heart Journal, 2020, 41, 1109-1111.	2.2	7
100	Co-expression of glycosylated aquaporin-1 and transcription factor NFAT5 contributes to aortic stiffness in diabetic and atherosclerosis-prone mice. Journal of Cellular and Molecular Medicine, 2020, 24, 2857-2865.	3.6	6
101	The nomenclature vagaries for the clinical manifestations of myocardial ischemic syndromes – A call to action. International Journal of Cardiology, 2020, 304, 5-7.	1.7	2
102	Simulated hyperglycemia impairs insulin signaling in endothelial cells through a hyperosmolar mechanism. Vascular Pharmacology, 2020, 130, 106678.	2.1	15
103	Aspirin for primary cardiovascular prevention: why the wonder drug should not be precipitously dismissed. Polish Archives of Internal Medicine, 2020, 130, 121-129.	0.4	4
104	Fourth universal definition of myocardial infarction (2018). European Heart Journal, 2019, 40, 237-269.	2.2	2,687
105	CHA ₂ DS ₂ -VASc score and adverse outcomes in middle-aged individuals without atrial fibrillation. European Journal of Preventive Cardiology, 2019, 26, 1987-1997.	1.8	25
106	Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe). BMC Cardiovascular Disorders, 2019, 19, 165.	1.7	29
107	Prognostic Role of Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Low-to-Intermediate Sudden Cardiac Death Risk Score. American Journal of Cardiology, 2019, 124, 1286-1292.	1.6	38
108	Hydroxytyrosol Modulates Adipocyte Gene and miRNA Expression Under Inflammatory Condition. Nutrients, 2019, 11, 2493.	4.1	38

#	ARTICLE	IF	CITATIONS
109	Is there an "atherosclerotic continuum"™ from angina with unobstructed coronary arteries to MINOCA? Reply. <i>European Heart Journal</i> , 2019, 40, 1988-1988.	2.2	1
110	Determinants of left atrium thrombi in scheduled cardioversion: an ENSURE-AF study analysis. <i>Europace</i> , 2019, 21, 1633-1638.	1.7	15
111	Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina. <i>Cardiovascular Diabetology</i> , 2019, 18, 144.	6.8	33
112	The global Edoxaban Treatment in routine clinical practice (ETNA) noninterventional study program: rationale and design. <i>Clinical Cardiology</i> , 2019, 42, 1147-1154.	1.8	16
113	Platelet Indices and Risk of Death and Cardiovascular Events: Results from a Large Population-Based Cohort Study. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1773-1784.	3.4	22
114	Impact of Sex Differences and Diabetes on Coronary Atherosclerosis and Ischemic Heart Disease. <i>Journal of Clinical Medicine</i> , 2019, 8, 98.	2.4	49
115	Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation. <i>American Journal of Medicine</i> , 2019, 132, 749-757.e5.	1.5	48
116	Deficiency of NDUFC2: Cause or bystander in acute coronary syndromes?. <i>International Journal of Cardiology</i> , 2019, 286, 134-135.	1.7	2
117	Proteomic analysis of the secretome of adipose tissue-derived murine mesenchymal cells overexpressing telomerase and myocardin. <i>Journal of Molecular and Cellular Cardiology</i> , 2019, 131, 171-186.	1.9	17
118	The epicardial adipose tissue and the coronary arteries: dangerous liaisons. <i>Cardiovascular Research</i> , 2019, 115, 1013-1025.	3.8	44
119	Antioxidant and Anti-Inflammatory Properties of Nigella sativa Oil in Human Pre-Adipocytes. <i>Antioxidants</i> , 2019, 8, 51.	5.1	96
120	Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention of thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF). <i>BMJ Open</i> , 2019, 9, e022478.	1.9	50
121	Oxidative stress and vascular stiffness in hypertension: A renewed interest for antioxidant therapies?. <i>Vascular Pharmacology</i> , 2019, 116, 45-50.	2.1	24
122	The co-predictive value of a cardiovascular score for CV outcomes in diabetic patients with no atrial fibrillation. <i>Diabetes/Metabolism Research and Reviews</i> , 2019, 35, e3145.	4.0	5
123	Thrombotic and hemorrhagic burden in women: Gender-related issues in the response to antithrombotic therapies. <i>International Journal of Cardiology</i> , 2019, 286, 198-207.	1.7	23
124	The Extra-Virgin Olive Oil Polyphenols Oleocanthal and Oleacein Counteract Inflammation-Related Gene and miRNA Expression in Adipocytes by Attenuating NF- κ B Activation. <i>Nutrients</i> , 2019, 11, 2855.	4.1	63
125	The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section "Special Situations". <i>Thrombosis and Haemostasis</i> , 2019, 119, 014-038.	3.4	28
126	Spontaneous conversion in patients with non-valvular atrial fibrillation planned for electrical cardioversion: A subanalysis of the Edoxaban versus warfarin in subjects Undergoing cardioversion Of Atrial Fibrillation (ENSURE-AF) trial. <i>American Heart Journal</i> , 2019, 209, 131-135.	2.7	1

#	ARTICLE	IF	CITATIONS
127	Design and rationale of the Edoxaban Treatment in routine clinical practice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 97-104.	1.5	24
128	Mid-term outcomes after percutaneous interventions in coronary bifurcations. <i>International Journal of Cardiology</i> , 2019, 283, 78-83.	1.7	33
129	The first 3500 years of aspirin history from its roots – A concise summary. <i>Vascular Pharmacology</i> , 2019, 113, 1-8.	2.1	132
130	Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. <i>Nature Reviews Cardiology</i> , 2019, 16, 113-130.	13.7	73
131	Aspirin for primary cardiovascular prevention: advice for a decisional strategy still based on risk stratification. <i>Anatolian Journal of Cardiology</i> , 2019, 23, 70-78.	0.9	11
132	Determinants of long-term clinical outcomes in patients with angina but without obstructive coronary artery disease: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2018, 39, 2135-2146.	2.2	105
133	Scoring atherosclerosis in the search of evidence-based personalized medicine. <i>International Journal of Cardiology</i> , 2018, 261, 30-31.	1.7	1
134	Percutaneous coronary interventions for non-ST elevation acute coronary syndromes – The two faces of inappropriateness. <i>International Journal of Cardiology</i> , 2018, 255, 20-21.	1.7	0
135	Diabetic macroangiopathy: Pathogenetic insights and novel therapeutic approaches with focus on high glucose-mediated vascular damage. <i>Vascular Pharmacology</i> , 2018, 107, 27-34.	2.1	47
136	Endothelial permeability, LDL deposition, and cardiovascular risk factors – a review. <i>Cardiovascular Research</i> , 2018, 114, 35-52.	3.8	208
137	Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy. <i>International Journal of Cardiology</i> , 2018, 265, 141-147.	1.7	38
138	Grading of aortic stenosis severity: a head-to-head comparison between cardiac magnetic resonance imaging and echocardiography. <i>Radiologia Medica</i> , 2018, 123, 643-654.	7.7	16
139	Innate and adaptive immunity in atherosclerosis. <i>Vascular Pharmacology</i> , 2018, 107, 67-77.	2.1	46
140	Oral anticoagulants for atrial fibrillation and acute coronary syndrome with or without stenting. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, e40-e45.	1.5	2
141	Coronary computed tomography angiography, ECG stress test and nuclear imaging as sources of false-positive results in the detection of coronary artery disease. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, e133-e138.	1.5	3
142	Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy. <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 74-84.	1.6	21
143	Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (from the Edoxaban versus warfarin in subjects Undergoing cardioversion of Atrial Fibrillation) (EDOXAN). <i>Journal of Cardiovascular Medicine</i> , 2018, 19, e133-e138.	1.5	3
144	Non-vitamin K Antagonist Oral Anticoagulants for Mechanical Heart Valves. <i>Circulation</i> , 2018, 138, 1356-1365.	1.6	30

#	ARTICLE	IF	CITATIONS
145	Prognostic Role of Cardiac Magnetic Resonance in Arrhythmogenic Right Ventricular Cardiomyopathy. <i>American Journal of Cardiology</i> , 2018, 122, 1745-1753.	1.6	28
146	Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries. <i>International Journal of Cardiology</i> , 2018, 270, 160-166.	1.7	24
147	Mechanical prosthetic heart valves: Quality of anticoagulation and thromboembolic risk. The observational multicenter PLECTRUM study. <i>International Journal of Cardiology</i> , 2018, 267, 68-73.	1.7	36
148	Cell based mechanosensing in vascular patho-biology: More than a simple go-with the flow. <i>Vascular Pharmacology</i> , 2018, 111, 7-14.	2.1	13
149	Sex Implications in the Response to Anticoagulant Therapy in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018, 72, 283-286.	2.8	3
150	The safety and efficacy of non-vitamin K antagonist oral anticoagulants in atrial fibrillation in the elderly. <i>International Journal of Cardiology</i> , 2018, 265, 118-124.	1.7	18
151	Three-dimensional echographic evaluation of carotid artery disease. <i>Journal of Cardiovascular Echography</i> , 2018, 28, 218.	0.4	17
152	The left atrial appendage: from embryology to prevention of thromboembolism. <i>European Heart Journal</i> , 2017, 38, ehw159.	2.2	53
153	Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017, 69, 409-419.	2.8	67
154	Diabetic microangiopathy: Pathogenetic insights and novel therapeutic approaches. <i>Vascular Pharmacology</i> , 2017, 90, 1-7.	2.1	111
155	Oral anticoagulant use in octogenarian European patients with atrial fibrillation: A subanalysis of PREFER in AF. <i>International Journal of Cardiology</i> , 2017, 232, 98-104.	1.7	16
156	Edoxaban in Atrial Fibrillation and Venous Thromboembolism – Ten Key Questions and Answers: A Practical Guide. <i>Advances in Therapy</i> , 2017, 34, 620-637.	2.9	8
157	Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation. <i>Heart</i> , 2017, 103, 1024-1030.	2.9	104
158	Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. <i>Circulation</i> , 2017, 135, 1273-1275.	1.6	133
159	Intracardiac thrombi during warfarin anticoagulation - A case report and a brief literature review. <i>Cor Et Vasa</i> , 2017, 59, e277-e281.	0.1	4
160	The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight – a systematic literature review. <i>Clinical Research in Cardiology</i> , 2017, 106, 565-572.	3.3	50
161	Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017, 24, 331-339.	2.2	8
162	Aspirin in heart failure: don't throw the baby (aspirin) out with the bathwater. <i>European Journal of Heart Failure</i> , 2017, 19, 1089-1094.	7.1	3

#	ARTICLE	IF	CITATIONS
163	Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease. Journal of the American College of Cardiology, 2017, 69, 1363-1371.	2.8	102
164	Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients With Atrial Fibrillation: A Subanalysis From the PREFER in AF (Prevention of Thromboembolism and Bleeding Outcomes in Very Elderly Patients With Atrial Fibrillation) Trial. JAMA, 2017, 317, 137-145.	3.7	137
165	Impact of statin therapy intensity on endothelial progenitor cells after percutaneous coronary intervention in diabetic patients. The REMEDY-EPC late study. International Journal of Cardiology, 2017, 244, 112-118.	1.7	10
166	Non-Vitamin K Antagonist Oral Anticoagulants for Cardioversion in Atrial Fibrillation: An Updated Meta-analysis. American Journal of Medicine, 2017, 130, 457-461.	1.5	17
167	Stroke prevention in atrial fibrillation: Past, present and future. Thrombosis and Haemostasis, 2017, 117, 1230-1239.	3.4	346
168	Is Complete Revascularisation Mandated for all Patients with Multivessel Coronary Artery Disease?. Interventional Cardiology Review, 2017, 13, 45.	1.6	11
169	The acute impact of high-dose lipid-lowering treatment on endothelial progenitor cells in patients with coronary artery disease: The REMEDY-EPC early substudy. PLoS ONE, 2017, 12, e0172800.	2.5	10
170	Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis - Task Force on Anticoagulants in Heart Disease. Thrombosis and Haemostasis, 2016, 115, 685-711.	3.4	24
171	Inflammation and thrombosis - testing the hypothesis with anti-inflammatory drug trials. Thrombosis and Haemostasis, 2016, 116, 1012-1021.	3.4	42
172	Rosuvastatin for Reduction of Myocardial Damage during Coronary Angioplasty - the Remedy Trial. Cardiovascular Drugs and Therapy, 2016, 30, 465-472.	2.6	5
173	ST segment/heart rate hysteresis improves the diagnostic accuracy of ECG stress test for coronary artery disease in patients with left ventricular hypertrophy. European Journal of Preventive Cardiology, 2016, 23, 1632-1639.	1.8	6
174	How safe are non-vitamin K antagonist oral anticoagulants in atrial fibrillation?. European Heart Journal Supplements, 2016, 18, 11-16.	0.1	1
175	All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT. Data in Brief, 2016, 7, 1541-1550.	1.0	1
176	Do we need P2Y12 inhibitor pretreatment in non-ST elevation acute coronary syndrome?. Revista Portuguesa De Cardiologia (English Edition), 2016, 35, 319-321.	0.2	0
177	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Journal of Cardio-thoracic Surgery, 2016, 50, e1-e88.	1.4	754
178	Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48. Clinical Cardiology, 2016, 39, 345-346.	1.8	53
179	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 2016, 37, 2893-2962.	2.2	5,689
180	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace, 2016, 18, 1609-1678.	1.7	3,523

#	ARTICLE	IF	CITATIONS
181	Von Willebrand factor, ADAMTS13, and coronary microvascular obstruction: beautiful hypotheses, ugly facts. <i>Cardiovascular Research</i> , 2016, 111, 169-171.	3.8	5
182	Heart failure due to right ventricular apical pacing: the importance of flow patterns. <i>Europace</i> , 2016, 18, 1679-1688.	1.7	33
183	Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation. <i>American Journal of Medicine</i> , 2016, 129, 1117-1123.e2.	1.5	14
184	Do we need P2Y12 inhibitor pretreatment in non-ST elevation acute coronary syndrome?. <i>Revista Portuguesa De Cardiologia</i> , 2016, 35, 319-321.	0.5	1
185	Stroke Prevention in Atrial Fibrillation: A Clinical Perspective on Trials of the Novel Oral Anticoagulants. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 201-214.	2.6	18
186	Cholesterol-lowering interventions and stroke: Insights from IMPROVE-IT. <i>Atherosclerosis</i> , 2016, 248, 216-218.	0.8	18
187	Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR) α/δ agonist aleglitazar in attenuating TNF- α -mediated inflammation and insulin resistance in human adipocytes. <i>Pharmacological Research</i> , 2016, 107, 125-136.	7.1	43
188	Targeting thrombin long-term after an acute coronary syndrome: Opportunities and challenges. <i>Vascular Pharmacology</i> , 2016, 81, 1-14.	2.1	8
189	High glucose-induced hyperosmolarity contributes to COX-2 expression and angiogenesis: implications for diabetic retinopathy. <i>Cardiovascular Diabetology</i> , 2016, 15, 18.	6.8	67
190	History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. <i>American Heart Journal</i> , 2016, 175, 175-183.	2.7	16
191	Effect of High-Dose Atorvastatin Reload on the Release of Endothelial Progenitor Cells in Patients on Long-Term Statin Treatment Who Underwent Percutaneous Coronary Intervention (from the Tj ETQq1 1 0.78431416 BT /Overdock 10 T	4.6	10
192	Extra virgin olive oil rich in polyphenols modulates VEGF-induced angiogenic responses by preventing NADPH oxidase activity and expression. <i>Journal of Nutritional Biochemistry</i> , 2016, 28, 19-29.	4.2	53
193	C1q/TNF-related protein-1: an adipokine marking and promoting atherosclerosis. <i>European Heart Journal</i> , 2016, 37, 1762-1771.	2.2	75
194	Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial. <i>Europace</i> , 2016, 18, 6-11.	1.7	38
195	Ultra-Sensitive Copeptin and Cardiac Troponin in Diagnosing Non-ST-Segment Elevation Acute Coronary Syndromesâ€”The COPACS Study. <i>American Journal of Medicine</i> , 2016, 129, 105-114.	1.5	8
196	Complete myocardial revascularization confers a larger clinical benefit when performed with state-of-the-art techniques in high-risk patients with multivessel coronary artery disease: A meta-analysis of randomized and observational studies. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 3-12.	1.7	60
197	Bivalirudin for acute coronary syndromes: premises, promises and doubts. <i>Thrombosis and Haemostasis</i> , 2015, 113, 698-707.	3.4	14
198	Additive Regulation of Adiponectin Expression by the Mediterranean Diet Olive Oil Components Oleic Acid and Hydroxytyrosol in Human Adipocytes. <i>PLoS ONE</i> , 2015, 10, e0128218.	2.5	51

#	ARTICLE	IF	CITATIONS
199	Cancer after intense and prolonged antiplatelet therapies – fact or fiction?. <i>Thrombosis and Haemostasis</i> , 2015, 114, 1100-1103.	3.4	4
200	Cardiovascular morbidity and mortality related to orthostatic hypotension: a meta-analysis of prospective observational studies. <i>European Heart Journal</i> , 2015, 36, 1609-1617.	2.2	238
201	The new ACCF/AHA guidelines on the treatment of dyslipidemia: pros. <i>Internal and Emergency Medicine</i> , 2015, 10, 115-117.	2.0	1
202	Elevated glycosylated albumin and reduced endogenous secretory receptor for advanced glycation endproducts levels in serum predict major adverse cardio-cerebral events in patients with type 2 diabetes and stable coronary artery disease. <i>International Journal of Cardiology</i> , 2015, 197, 241-247.	1.7	28
203	Pathways and Drugs in Pulmonary Arterial Hypertension – Focus on the Role of Endothelin Receptor Antagonists. <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 469-479.	2.6	20
204	Transplantation of adipose tissue mesenchymal cells conjugated with VEGF-releasing microcarriers promotes repair in murine myocardial infarction. <i>Cardiovascular Research</i> , 2015, 108, 39-49.	3.8	54
205	Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2015, 36, ehv304.	2.2	175
206	Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials. <i>American Journal of Medicine</i> , 2015, 128, 1007-1014.e2.	1.5	32
207	Circulating endothelial progenitor cells: Do they live up to their name?. <i>Vascular Pharmacology</i> , 2015, 67-69, 2-5.	2.1	49
208	Determinants of subacute response to clopidogrel: relative impact of CYP2C19 genotype and PGE1/adenylate cyclase signalling. <i>Thrombosis Research</i> , 2015, 136, 308-314.	1.7	8
209	Genetic determinants of cognitive responses to caffeine drinking identified from a double-blind, randomized, controlled trial. <i>European Neuropsychopharmacology</i> , 2015, 25, 798-807.	0.7	27
210	Orthostatic Hypotension. <i>Journal of the American College of Cardiology</i> , 2015, 66, 848-860.	2.8	333
211	Role and importance of ultrasound lung comets in acute cardiac care. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015, 4, 103-112.	1.0	19
212	Transcriptome-based identification of new anti-inflammatory and vasodilating properties of the n-3 fatty acid docosahexaenoic acid in vascular endothelial cell under proinflammatory conditions. <i>PLoS ONE</i> , 2015, 10, e0129652.	2.5	13
213	Aquaporin-1 and Sodium-Hydrogen Exchangers as Pharmacological Targets in Diabetic Atherosclerosis. <i>Current Drug Targets</i> , 2015, 16, 361-365.	2.1	15
214	Failure in evoking the trigeminal cardiac reflex by mandibular stretching in healthy volunteers. <i>Archives Italiennes De Biologie</i> , 2015, 153, 25-36.	0.4	3
215	Differences among western European countries in anticoagulation management of atrial fibrillation. <i>Thrombosis and Haemostasis</i> , 2014, 112, 833-841.	3.4	96
216	Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention of thromboembolic events – European Registry in Atrial Fibrillation (PREFER in AF). <i>Europace</i> , 2014, 16, 6-14.	1.7	349

#	ARTICLE	IF	CITATIONS
217	Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. <i>European Heart Journal</i> , 2014, 35, 1864-1872.	2.2	303
218	Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. <i>Thrombosis and Haemostasis</i> , 2014, 112, 781-782.	3.4	142
219	Potential roles of vessel wall heparan sulfate proteoglycans in atherosclerosis. <i>Vascular Pharmacology</i> , 2014, 60, 49-51.	2.1	8
220	Reprint of "Potential roles of vessel wall heparan sulfate proteoglycans in atherosclerosis". <i>Vascular Pharmacology</i> , 2014, 62, 120-122.	2.1	1
221	Ranolazine in the prevention of anthracycline cardiotoxicity. <i>Pharmacological Research</i> , 2014, 79, 88-102.	7.1	26
222	Transplantation of Mesenchymal Cells Improves Peripheral Limb Ischemia in Diabetic Rats. <i>Molecular Biotechnology</i> , 2014, 56, 438-448.	2.4	17
223	Proton pump inhibitors and clopidogrel: an association to avoid?. <i>Internal and Emergency Medicine</i> , 2014, 9, 11-22.	2.0	13
224	Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2141-2147.	2.8	308
225	The dynamics of the coronary collateral circulation. <i>Nature Reviews Cardiology</i> , 2014, 11, 191-197.	13.7	80
226	Angina Pectoris and Myocardial Ischemia in the Absence of Obstructive Coronary Artery Disease: Practical Considerations for Diagnostic Tests. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 453-463.	2.9	88
227	Hydroxytyrosol suppresses MMP-9 and COX-2 activity and expression in activated human monocytes via PKC α and PKC β 1 inhibition. <i>Atherosclerosis</i> , 2014, 232, 17-24.	0.8	113
228	Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients With Atrial Fibrillation. <i>Circulation</i> , 2014, 130, 1847-1858.	1.6	243
229	High glucose-induced hyperosmolarity impacts proliferation, cytoskeleton remodeling and migration of human induced pluripotent stem cells via aquaporin-1. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 2266-2275.	3.8	31
230	Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe. <i>Heart</i> , 2014, 100, 1625-1635.	2.9	27
231	Aspirin Therapy in Primary Cardiovascular Disease Prevention. <i>Journal of the American College of Cardiology</i> , 2014, 64, 319-327.	2.8	150
232	Co-Activation of Nuclear Factor- κ B and Myocardin/Serum Response Factor Conveys the Hypertrophy Signal of High Insulin Levels in Cardiac Myoblasts. <i>Journal of Biological Chemistry</i> , 2014, 289, 19585-19598.	3.4	23
233	The WOEST study: Critical considerations and applicability. <i>Cor Et Vasa</i> , 2014, 56, e254-e258.	0.1	9
234	Involvement of the TP receptor in TNF- α -induced endothelial tissue factor expression. <i>Vascular Pharmacology</i> , 2014, 62, 49-56.	2.1	26

#	ARTICLE	IF	CITATIONS
235	Long-Term Engraftment and Angiogenic Properties of Lentivirally Transduced Adipose Tissue-Derived Stromal Cells. <i>Molecular Biotechnology</i> , 2013, 54, 13-24.	2.4	6
236	Sodium- ⁺ hydrogen exchangers (NHE) in human cardiovascular diseases: Interfering strategies and their therapeutic applications. <i>Vascular Pharmacology</i> , 2013, 59, 127-130.	2.1	11
237	The new oral anticoagulants in atrial fibrillation: Once daily or twice daily?. <i>Vascular Pharmacology</i> , 2013, 59, 53-62.	2.1	23
238	Diabetes research in <i>Vascular Pharmacology</i> – An overview of 2011–2012. <i>Vascular Pharmacology</i> , 2013, 58, 251-252.	2.1	0
239	General mechanisms of coagulation and targets of anticoagulants (Section I). <i>Thrombosis and Haemostasis</i> , 2013, 109, 569-579.	3.4	165
240	Late Thrombosis After Double Versus Single Drug-Eluting Stent in the Treatment of Coronary Bifurcations. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 687-695.	2.9	74
241	Efficacy and Safety of Apixaban Compared With Warfarin at Different Levels of Predicted International Normalized Ratio Control for Stroke Prevention in Atrial Fibrillation. <i>Circulation</i> , 2013, 127, 2166-2176.	1.6	196
242	Glucose Metabolism, Hyperosmotic Stress, and Reprogramming of Somatic Cells. <i>Molecular Biotechnology</i> , 2013, 55, 169-178.	2.4	19
243	Parenteral anticoagulants in heart disease: Current status and perspectives (Section II). <i>Thrombosis and Haemostasis</i> , 2013, 109, 769-786.	3.4	154
244	Vitamin K antagonists in heart disease: Current status and perspectives (Section III). <i>Thrombosis and Haemostasis</i> , 2013, 110, 1087-1107.	3.4	347
245	Genetic determinants of blood pressure responses to caffeine drinking. <i>American Journal of Clinical Nutrition</i> , 2012, 95, 241-248.	4.7	54
246	Clinical Use of Aspirin in Ischemic Heart Disease: Past, Present and Future. <i>Current Pharmaceutical Design</i> , 2012, 18, 5215-5223.	1.9	12
247	Isolated troponin increase after percutaneous coronary interventions: Does it have prognostic relevance?. <i>Atherosclerosis</i> , 2012, 221, 297-302.	0.8	23
248	Atherogenesis and Diabetes: Focus on Insulin Resistance and Hyperinsulinemia. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012, 65, 309-313.	0.6	13
249	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. <i>Europace</i> , 2012, 14, 1385-1413.	1.7	2,319
250	Aterogénesis y diabetes: resistencia a la insulina e hiperinsulinemia. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 309-313.	1.2	23
251	Mediterranean diet polyphenols reduce inflammatory angiogenesis through MMP-9 and COX-2 inhibition in human vascular endothelial cells: A potentially protective mechanism in atherosclerotic vascular disease and cancer. <i>Archives of Biochemistry and Biophysics</i> , 2012, 527, 81-89.	3.0	275
252	New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1413-1425.	2.8	257

#	ARTICLE	IF	CITATIONS
253	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. <i>European Heart Journal</i> , 2012, 33, 2719-2747.	2.2	3,144
254	Relevance of new drug discovery to reduce NF- κ B activation in cardiovascular disease. <i>Vascular Pharmacology</i> , 2012, 57, 41-47.	2.1	41
255	Nitrates and Other Nitric Oxide Donors in Cardiology - Current Positioning and Perspectives. <i>Cardiovascular Drugs and Therapy</i> , 2012, 26, 55-69.	2.6	15
256	Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2011, 365, 699-708.	27.0	918
257	Stroke Prevention in Atrial Fibrillation: Current Status and Near-Future Directions. <i>American Journal of Medicine</i> , 2011, 124, 793-799.	1.5	19
258	Fraud in biomedical research – The role of journal Editors. <i>Life Sciences</i> , 2011, 89, 755-756.	4.3	1
259	Strong association of the APOA5-1131T>C gene variant and early-onset acute myocardial infarction. <i>Atherosclerosis</i> , 2011, 214, 397-403.	0.8	47
260	Net Clinical Benefit of Adding Clopidogrel to Aspirin Therapy in Patients With Atrial Fibrillation for Whom Vitamin K Antagonists Are Unsuitable. <i>Annals of Internal Medicine</i> , 2011, 155, 579.	3.9	119
261	Cellular and molecular mechanisms of vascular injury in diabetes – Part I: Pathways of vascular disease in diabetes. <i>Vascular Pharmacology</i> , 2011, 54, 68-74.	2.1	136
262	Cellular and molecular mechanisms of vascular injury in diabetes – Part II: Cellular mechanisms and therapeutic targets. <i>Vascular Pharmacology</i> , 2011, 54, 75-79.	2.1	53
263	Fraud in biomedical research – The role of journal Editors. <i>Vascular Pharmacology</i> , 2011, 55, 119-120.	2.1	3
264	n-3 Fatty Acids in Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2011, 364, 2439-2450.	27.0	508
265	Antiplatelet agents for the treatment and prevention of atherothrombosis. <i>European Heart Journal</i> , 2011, 32, 2922-2932.	2.2	203
266	Increased serum high-mobility group box-1 and cleaved receptor for advanced glycation endproducts levels and decreased endogenous secretory receptor for advanced glycation endproducts levels in diabetic and non-diabetic patients with heart failure. <i>European Journal of Heart Failure</i> , 2011, 13, 440-449.	7.1	65
267	Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. <i>European Heart Journal</i> , 2011, 32, 1854-1864.	2.2	343
268	Aspirin-triggered lipoxin in patients treated with aspirin and selective/nonselective COX-2 inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 303-306.	2.4	7
269	Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. <i>European Heart Journal</i> , 2010, 31, 2133-2140.	2.2	35
270	Long-term Use of Anti-inflammatory Drugs and Risk of Atrial Fibrillation. <i>Archives of Internal Medicine</i> , 2010, 170, 1450-5.	3.8	62

#	ARTICLE	IF	CITATIONS
271	Glycaemic control in acute coronary syndromes: prognostic value and therapeutic options. <i>European Heart Journal</i> , 2010, 31, 1557-1564.	2.2	54
272	Cholesterol-Lowering Interventions and Stroke. <i>Journal of the American College of Cardiology</i> , 2010, 55, 198-211.	2.8	88
273	Pharmacological modulation of vascular inflammation in atherothrombosis. <i>Annals of the New York Academy of Sciences</i> , 2010, 1207, 23-31.	3.8	21
274	Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2010, 31, 2369-2429.	2.2	4,635
275	Opportunities and Challenges in Nutrigenetics/Nutrigenomics and Health. <i>Journal of Nutrigenetics and Nutrigenomics</i> , 2010, 3, 137-143.	1.3	4
276	Nutraceuticals and Prevention of Atherosclerosis: Focus on ω -3 Polyunsaturated Fatty Acids and Mediterranean Diet Polyphenols. <i>Cardiovascular Therapeutics</i> , 2010, 28, e13-9.	2.5	89
277	Adipose Tissue-Derived Stem Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 1723-1729.	2.4	141
278	Increased glycated albumin and decreased esRAGE levels are related to angiographic severity and extent of coronary artery disease in patients with type 2 diabetes. <i>Atherosclerosis</i> , 2009, 206, 540-545.	0.8	69
279	The current role of anticoagulants in cardiovascular medicine. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, 595-604.	1.5	17
280	Prolonged exposure to high insulin impairs the endothelial PI3-kinase/Akt/nitric oxide signalling. <i>Thrombosis and Haemostasis</i> , 2009, 101, 345-350.	3.4	37
281	New anticoagulants for atrial fibrillation. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, 446-453.	1.5	4
282	Insulin potentiates cytokine-induced VCAM-1 expression in human endothelial cells. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2008, 1782, 511-516.	3.8	30
283	Awake Blood Pressure Variability, Inflammatory Markers and Target Organ Damage in Newly Diagnosed Hypertension. <i>Hypertension Research</i> , 2008, 31, 2137-2146.	2.7	75
284	Receiver operating characteristic (ROC) curves and the definition of threshold levels to diagnose coronary artery disease on electrocardiographic stress testing. Part II: The use of ROC curves in the choice of electrocardiographic stress test markers of ischaemia. <i>Journal of Cardiovascular Medicine</i> , 2008, 9, 22-31.	1.5	10
285	Homocysteine induces VCAM-1 gene expression through NF- κ B and NAD(P)H oxidase activation: protective role of Mediterranean diet polyphenolic antioxidants. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007, 293, H2344-H2354.	3.2	106
286	Both vitamin B6 and total homocysteine plasma levels predict long-term atherothrombotic events in healthy subjects. <i>European Heart Journal</i> , 2007, 28, 484-491.	2.2	33
287	Awake Systolic Blood Pressure Variability Correlates With Target-Organ Damage in Hypertensive Subjects. <i>Hypertension</i> , 2007, 50, 325-332.	2.7	251
288	Universal Definition of Myocardial Infarction. <i>Circulation</i> , 2007, 116, 2634-2653.	1.6	2,755

#	ARTICLE	IF	CITATIONS
289	Omega-3 fatty acids, atherogenesis, and endothelial activation. <i>Journal of Cardiovascular Medicine</i> , 2007, 8, S11-S14.	1.5	15
290	Management of pregnant women with artificial heart valves: inconsistency in ESC publications: reply. <i>European Heart Journal</i> , 2007, 28, 2419-2420.	2.2	0
291	Anticoagulants in heart disease: current status and perspectives. <i>European Heart Journal</i> , 2007, 28, 880-913.	2.2	119
292	n-3 Fatty Acids in the Treatment of Diabetic Patients. <i>Diabetes Care</i> , 2007, 30, 1012-1026.	8.6	110
293	Vasculoprotective potential of olive oil components. <i>Molecular Nutrition and Food Research</i> , 2007, 51, 1225-1234.	3.3	90
294	Rapid Decline of Collateral Circulation Increases Susceptibility to Myocardial Ischemia. <i>Journal of the American College of Cardiology</i> , 2006, 48, 59-65.	2.8	62
295	Nutritional mechanisms that influence cardiovascular disease. <i>American Journal of Clinical Nutrition</i> , 2006, 83, 421S-426S.	4.7	111
296	At Least 2 Distinct Pathways Generating Reactive Oxygen Species Mediate Vascular Cell Adhesion Molecule-1 Induction by Advanced Glycation End Products. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 1401-1407.	2.4	192
297	Simvastatin Attenuates Expression of Cytokine-inducible Nitric-oxide Synthase in Embryonic Cardiac Myoblasts. <i>Journal of Biological Chemistry</i> , 2005, 280, 13503-13511.	3.4	80
298	Recommendations for the management of patients after heart valve surgery. <i>European Heart Journal</i> , 2005, 26, 2463-2471.	2.2	488
299	Distal embolization during primary angioplasty: Histopathologic features and predictability. <i>American Heart Journal</i> , 2005, 150, 102-108.	2.7	97
300	Nutrients and Gene Expression. , 2004, 93, 99-133.		20
301	Effects of omega-3 fatty acids on cytokines and adhesion molecules. <i>Current Atherosclerosis Reports</i> , 2004, 6, 485-491.	4.8	55
302	From Asthma to Atherosclerosis – 5-Lipoxygenase, Leukotrienes, and Inflammation. <i>New England Journal of Medicine</i> , 2004, 350, 4-7.	27.0	158
303	Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) Pilot Study. <i>American Heart Journal</i> , 2004, 148, 180.	2.7	30
304	Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. <i>Cardiovascular Research</i> , 2004, 63, 582-592.	3.8	779
305	New cardiovascular risk factors: homocysteine and vitamins involved in homocysteine metabolism. <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , 2004, 5 Suppl 6, 19S-24S.	0.1	1
306	Antiarrhythmic effects of omega-3 fatty acids: from epidemiology to bedside. <i>American Heart Journal</i> , 2003, 146, 420-430.	2.7	61

#	ARTICLE	IF	CITATIONS
307	Olive Oil and Red Wine Antioxidant Polyphenols Inhibit Endothelial Activation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 622-629.	2.4	586
308	Low-dose aspirin in the primary prevention of cardiovascular disease: how to balance the benefits and the risks. <i>Italian Heart Journal: Official Journal of the Italian Federation of Cardiology</i> , 2003, 4, 228-31.	0.1	0
309	Low-Density Lipoprotein Level Reduction by the 3-Hydroxy-3-Methylglutaryl Coenzyme-A Inhibitor Simvastatin Is Accompanied by a Related Reduction of F ₂ -Isoprostane Formation in Hypercholesterolemic Subjects. <i>Circulation</i> , 2002, 106, 2543-2549.	1.6	114
310	Advanced Glycation End Products Activate Endothelium Through Signal-Transduction Receptor RAGE. <i>Circulation</i> , 2002, 105, 816-822.	1.6	501
311	Quenching of Intracellular ROS Generation as a Mechanism for Oleate-Induced Reduction of Endothelial Activation and Early Atherogenesis. <i>Thrombosis and Haemostasis</i> , 2002, 88, 335-344.	3.4	73
312	Quenching of intracellular ROS generation as a mechanism for oleate-induced reduction of endothelial activation and early atherogenesis. <i>Thrombosis and Haemostasis</i> , 2002, 88, 335-44.	3.4	19
313	¹¹¹ In Platelet Scintigraphy for the Noninvasive Detection of Carotid Plaque Thrombosis. <i>Stroke</i> , 2001, 32, 719-727.	2.0	27
314	n-3 fatty acids: Antiatherosclerotic effects. <i>Lipids</i> , 2001, 36, S69-S78.	1.7	49
315	Endothelial dysfunctions: common denominators in vascular disease. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2000, 3, 453-467.	2.5	45
316	Estrogens and Glucocorticoids Inhibit Endothelial Vascular Cell Adhesion Molecule-1 Expression by Different Transcriptional Mechanisms. <i>Circulation Research</i> , 2000, 87, 19-25.	4.5	171
317	Oleic Acid Inhibits Endothelial Activation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 220-228.	2.4	210
318	Soluble Vascular Cell Adhesion Molecule-1 as a Biohumoral Correlate of Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 2646-2654.	2.4	243
319	Control of endothelial leukocyte adhesion molecules by fatty acids. <i>Lipids</i> , 1996, 31, S57-S63.	1.7	129
320	Selective inhibition of thromboxane-related platelet function by low-dose aspirin in patients after myocardial infarction. <i>American Journal of Cardiology</i> , 1985, 55, 589-590.	1.6	32